Effect of alirocumab dose increase on LDL lowering and lipid goal attainment in patients with dyslipidemia

OBJECTIVES: The objective of this study is to report the dose response in ODYSSEY phase 3 clinical trials of proprotein convertase subtilisin kexin type 9 inhibition with alirocumab in patients not at prespecified lipid goals who received a per-protocol dose increase from 75 every 2 weeks (Q2W) to 1...

Descripción completa

Detalles Bibliográficos
Autores principales: Kastelein, John J.P., Kereiakes, Dean J., Cannon, Christopher P., Bays, Harold E., Minini, Pascal, Lee, L. Veronica, Maroni, Jaman, Farnier, Michel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5400401/
https://www.ncbi.nlm.nih.gov/pubmed/27740972
http://dx.doi.org/10.1097/MCA.0000000000000438

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5400401/
https://www.ncbi.nlm.nih.gov/pubmed/27740972
http://dx.doi.org/10.1097/MCA.0000000000000438

Ejemplares similares